Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Abstract Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab),...

Full description

Bibliographic Details
Main Authors: Virginie Lemiale, Anne-Pascale Meert, François Vincent, Michael Darmon, Philippe R. Bauer, Andry Van de Louw, Elie Azoulay, Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH)
Format: Article
Language:English
Published: SpringerOpen 2019-02-01
Series:Annals of Intensive Care
Subjects:
Immunotherapy
Cancer
ICU
Adverse events
Online Access:http://link.springer.com/article/10.1186/s13613-019-0487-x

Internet

http://link.springer.com/article/10.1186/s13613-019-0487-x

Similar Items